See the full article from Wisconsin State Journal.
Cellectar Biosciences, Madison, says it is starting phase-two clinical trials on a compound to treat patients with multiple myeloma and other blood cancers.
As many as 80 patients at up to 15 centers across the U.S. will receive one dose of Cellectar’s CLR-131 with the possibility of a second dose about three to six months later. They also will be given dexamethasone — a corticosteroid used to prevent the release of substances that cause inflammation — for up to 12 weeks.
Locations of the centers are not being disclosed.